Danish BioTech Samplix secures €25 million in first close of financing round to scale antibody discovery
Samplix, a Danish BioTech company developing droplet microfluidics technology for functional single-cell analysis, has secured a €25 million first closing of its new financing round. The financing comprises €3 million in new capital and €22 million in shareholder convertible bonds. It was led by WLanholding GmbH, a privately owned European investment firm with participation from […] The post…
Danish biotech company Samplix has successfully secured €25 million in its first round of financing, aiming to scale its antibody discovery technology. The funding round, led by WLanholding GmbH, a private European investment firm, includes an additional €3 million in new capital and €22 million in shareholder convertible bonds.
WLanholding GmbH, led by Dr. Werner Lanthaler, a former CEO of Evotec, expressed their excitement in partnering with Samplix and supports the company in its growth. Samplix, headquartered in Birkerød, was founded in 2013 with the mission of making high-throughput cellular screening accessible without specialized instruments. Their core product, the Xdrop platform, employs droplet microfluidics technology to perform high-throughput, functional single-cell analysis.
The technology enables researchers to observe cell behavior in millions of tiny droplets, which act as self-contained reaction vessels. Samplix's platform is widely used in antibody discovery, immunotherapy, cell line development, genomic editing, and other functional single-cell research. The investment will help the company strengthen its balance sheet, expand commercial adoption of its Xdrop platform, particularly in the antibody discovery space, and explore opportunities in AI-driven drug discovery.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
